A Multivalent Pan-Ebolavirus Nanoparticle Vaccine Provides Protection in Rodents from Lethal Infection by Adapted Zaire and Sudan Viruses
Brunette, N.; Weidle, C.; Wrenn, S. P.; Fiala, B.; Ravichandran, R.; Carr, K. D.; Zak, S. E.; Zumbrun, E. E.; Bakken, R. R.; Murphy, M.; Chan, S.; Skotheim, R.; Borst, A. J.; Carter, L.; Correnti, C. E.; Dye, J. M.; Baker, D.; King, N. P.; Stewart, L. J.
Show abstract
Both Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV) are members of the family Filoviridae, first discovered in 1976 during outbreaks of hemorrhagic fever in northern Zaire and southern Sudan. Ebola virus disease outbreaks are major public health events because of their potential for human-to-human transmission with high case fatality rates. Filoviral surface glycoproteins (GPs) are known to be the primary targets of neutralizing antibodies for protection from disease, and are the relevant immunogens in the two approved EBOV vaccines. Here we describe the design, electron microscopy-based structural characterization, and efficacy testing of a series of icosahedral I53-50 nanoparticles displaying prefusion trimeric EBOV and SUDV GP antigens. Mice and guinea pigs vaccinated with either a cocktail of EBOV-GP-I53-50 plus SUDV-GP-I53-50 or mosaic EBOV / SUDV-GP-I53-50 nanoparticles were protected from death or severe clinical signs of disease and weight loss, respectively, when challenged with either mouse-adapted EBOV or guinea pig-adapted SUDV.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Targeting HIV Env immunogens to B cell follicles in non-human primates through immune complex or protein nanoparticle formulations 97%
- Enhanced protective efficacy of a novel, thermostable, RBD-S2 fusion immunogen against SARS-CoV-2 and its variants 96%
- Immunofocusing on the conserved fusion peptide of HIV envelope glycoprotein in rhesus macaques 96%
Similar papers in this journal
- A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses 98%
- Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine 96%
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 96%
Similar papers in this journal
Similar papers in this journal
- Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative 97%
- Development of a thermostable and broadly neutralizing pan-sarbecovirus vaccine candidate 95%
- Cholesterol-Dependent Membrane Deformation by Metastable Viral Capsids Facilitates Entry 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.